Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% – Here’s What Happened

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) were down 1.1% during trading on Tuesday . The company traded as low as $5.88 and last traded at $6.06. Approximately 5,260,868 shares traded hands during trading, a decline of 79% from the average daily volume of 25,323,674 shares. The stock had previously closed at $6.13.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Finally, Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Stock Down 3.7 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of -3.88 and a beta of 0.85. The business’s fifty day moving average is $7.57 and its two-hundred day moving average is $7.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.42) EPS. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc grew its holdings in Recursion Pharmaceuticals by 0.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock worth $2,774,000 after acquiring an additional 1,300 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after acquiring an additional 1,353 shares in the last quarter. Axxcess Wealth Management LLC grew its holdings in Recursion Pharmaceuticals by 4.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after acquiring an additional 1,795 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in Recursion Pharmaceuticals by 7.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock worth $176,000 after acquiring an additional 1,875 shares in the last quarter. Finally, Wedmont Private Capital grew its holdings in Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after acquiring an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.